| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
4-Hydroxybenzamide targets pathways involved in atherosclerosis, with potential to slow its progression. The compound may interact with enzymes and receptors involved in lipid metabolism, inflammation, and oxidative stress. Its phenolic hydroxyl group allows for radical scavenging activity, while the amide group may facilitate hydrogen bonding interactions with biological targets. Specific molecular targets are not extensively characterized in the literature.
|
|---|---|
| ln Vitro |
In vitro activity data for 4-Hydroxybenzamide are limited in the literature. The compound has been studied for its potential to slow the progression of atherosclerosis, suggesting activity in models of vascular inflammation and lipid metabolism. It may exhibit antioxidant activity through radical scavenging mechanisms. Specific IC₅₀ values and detailed activity profiles are not extensively documented.
|
| ln Vivo |
In vivo activity data for 4-Hydroxybenzamide are limited. The compound has been reported to have potential for slowing the progression of atherosclerosis, suggesting possible in vivo efficacy in animal models of cardiovascular disease. However, specific animal studies detailing its therapeutic effects and pharmacokinetics are not extensively documented.
|
| Enzyme Assay |
The non-cellular enzyme/receptor binding assays for 4-Hydroxybenzamide would typically involve antioxidant activity evaluation using chemical assays such as DPPH, ABTS, and FRAP. The compound's ability to scavenge free radicals is measured spectrophotometrically. For atherosclerosis research, assays could include measuring the compound's effect on LDL oxidation or its ability to inhibit enzymes involved in lipid metabolism such as HMG-CoA reductase. However, specific assays are not extensively documented.
|
| Cell Assay |
In vitro cellular assays for 4-Hydroxybenzamide could involve the use of vascular endothelial cells or macrophages to evaluate its effects on atherosclerosis-related processes. Cells are treated with various concentrations of the compound, and markers of inflammation (e.g., cytokine production, adhesion molecule expression), oxidative stress (e.g., ROS levels), and lipid metabolism (e.g., cholesterol uptake, foam cell formation) are assessed. Cell viability is assessed to ensure observed effects are not due to cytotoxicity.
|
| Animal Protocol |
In vivo animal studies for 4-Hydroxybenzamide are not extensively documented. Based on its potential to slow atherosclerosis progression, typical study designs would involve atherosclerosis-prone mouse models (e.g., ApoE⁻/⁻ or LDLR⁻/⁻ mice fed a high-fat diet). The compound would be administered orally. Atherosclerotic lesion面积, lipid profiles, inflammatory markers, and oxidative stress parameters would be evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 4-Hydroxybenzamide are not extensively characterized. As a small molecule with molecular weight 137.14, it is expected to have good oral absorption. The compound contains both a phenolic hydroxyl group and an amide group, which may undergo phase II conjugation (glucuronidation and sulfation) and possibly hydrolysis. Specific PK parameters such as half-life, Cmax, and bioavailability are not well documented.
|
| Toxicity/Toxicokinetics |
Toxicological data for 4-Hydroxybenzamide are limited. As a naturally occurring benzamide derivative, it is generally considered to have low toxicity. However, comprehensive toxicology studies are not available. The compound may cause skin and eye irritation upon contact. Standard laboratory safety precautions should be observed when handling this compound.
|
| Additional Infomation |
p-Hydroxybenzamide is one of the benzamide compounds. It has been reported that 4-hydroxybenzamide exists in Xanthomonas flavus, Anabaena, and Streptomyces, and relevant data are available for reference.
4-Hydroxybenzamide is a research-grade natural product intended for laboratory use only. It is not approved for clinical use as a therapeutic agent. Its primary applications include studying the potential of benzamide derivatives in atherosclerosis research, investigating the biological activities of natural products from Berberis pruinosa and marine sponges, and serving as a chemical intermediate for the synthesis of more complex molecules. The compound is also known as p-Hydroxybenzamide. |
| Molecular Formula |
C7H7NO2
|
|---|---|
| Molecular Weight |
137.1360
|
| Exact Mass |
137.047
|
| CAS # |
619-57-8
|
| PubChem CID |
65052
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
345.3±25.0 °C at 760 mmHg
|
| Melting Point |
161-162 °C(lit.)
|
| Flash Point |
162.6±23.2 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.612
|
| LogP |
0.25
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
128
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C1C([H])=C([H])C(C(N([H])[H])=O)=C([H])C=1[H]
|
| InChi Key |
QXSAKPUBHTZHKW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H7NO2/c8-7(10)5-1-3-6(9)4-2-5/h1-4,9H,(H2,8,10)
|
| Chemical Name |
4-hydroxybenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2918 mL | 36.4591 mL | 72.9182 mL | |
| 5 mM | 1.4584 mL | 7.2918 mL | 14.5836 mL | |
| 10 mM | 0.7292 mL | 3.6459 mL | 7.2918 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
